- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-1827
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Biomarkers of response to PD-1 pathway blockade ; volume:126 ; number:12 ; day:28 ; month:2 ; year:2022 ; pages:1663-1675 ; date:6.2022
British journal of cancer ; 126, Heft 12 (28.2.2022), 1663-1675, 6.2022
- Urheber
-
Li, Hanxiao
van der Merwe, P. Anton
Sivakumar, Shivan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-022-01743-4
- URN
-
urn:nbn:de:101:1-2022080419523748619150
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Li, Hanxiao
- van der Merwe, P. Anton
- Sivakumar, Shivan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
PD ‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFNγ Responses of HIV-Infected Persons on Antiretroviral Therapy
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/PD ‐1 blockade therapy
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
PD ‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFNγ Responses of HIV-Infected Persons on Antiretroviral Therapy
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/PD ‐1 blockade therapy
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
PD ‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFNγ Responses of HIV-Infected Persons on Antiretroviral Therapy
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/PD ‐1 blockade therapy
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders